Safety of prolonged treatment with bedaquiline in programmatic conditions

Bedaquiline is now considered a first-line medicine for treatment of rifampicin-resistant tuberculosis (RR-TB). We evaluated the safety of treatment with bedaquiline for longer than 190 days in individuals with RR-TB under programmatic conditions. In a prospective cohort study enrolling pulmonary RR...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhurkin, Dzmitriy, Gurbanova, Elmira, Campbell, Jonathon R., Menzies, Dick, Setkina, Svetlana, Hurevich, Hennadz, Solodovnikova, Varvara, Viatushka, Dzmitry, Altraja, Alan, Skrahina, Alena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108964/
https://www.ncbi.nlm.nih.gov/pubmed/35586446
http://dx.doi.org/10.1183/23120541.00685-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108964/
https://www.ncbi.nlm.nih.gov/pubmed/35586446
http://dx.doi.org/10.1183/23120541.00685-2021

Ejemplares similares